Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression.

BACKGROUND This analysis explored the relationship between ratings on HAM-D-17 or YMRS and those on the depressive or manic subscale of CGI-S for schizoaffective disorder (CGI-S-SCA). METHODS This post hoc analysis used the database (N=614) from two 6-week, randomized, placebo-controlled studies of paliperidone ER versus placebo in symptomatic subjects with schizoaffective disorder assessed using HAM-D-17, YMRS, and CGI-S-SCA scales. Parametric and nonparametric regression models explored the relationships between ratings on YMRS and HAM-D-17 and on depressive and manic domains of the CGI-S-SCA from baseline to the 6-week end point. A clinically meaningful improvement was defined as a change of 1 point in the CGI-S-SCA score. No adjustment was made for multiplicity. RESULTS Multiple linear regression models suggested that a 1-point change in the depressive domain of CGI-S-SCA corresponded to an average 3.6-point (SE=0.2) change in HAM-D-17 score. Similarly, a 1-point change in the manic domain of CGI-S-SCA corresponded to an average 5.8-point (SE=0.2) change in YMRS score. Results were confirmed using local and cumulative logistic regression models in addition to equipercentile linking. LIMITATIONS Lack of subjects scoring over the complete range of possible scores may limit broad application of the analyses. CONCLUSION Clinically meaningful score changes in depressive and manic domains of CGI-S-SCA corresponded to approximately 4- and 6-point score changes on HAM-D-17 and YMRS, respectively, in symptomatic subjects with schizoaffective disorder.

[1]  J. Calabrese,et al.  Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. , 2011, The Journal of clinical psychiatry.

[2]  E. Vieta,et al.  Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. , 2001, The Journal of clinical psychiatry.

[3]  J. Lindenmayer,et al.  A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. , 2010, The Journal of clinical psychiatry.

[4]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[5]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[6]  I. Turkoz,et al.  Role of paliperidone extended-release in treatment of schizoaffective disorder , 2010, Neuropsychiatric disease and treatment.

[7]  Stefan Leucht,et al.  Clinical implications of Brief Psychiatric Rating Scale scores. , 2005, The British journal of psychiatry : the journal of mental science.

[8]  J. Kane,et al.  Linking the PANSS, BPRS, and CGI: Clinical Implications , 2006, Neuropsychopharmacology.

[9]  Stefan Leucht,et al.  What does the PANSS mean? , 2005, Schizophrenia Research.

[10]  Peter B. Jones,et al.  The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.

[11]  J. Bartko,et al.  Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. , 2012, Innovations in clinical neuroscience.

[12]  T. Furukawa,et al.  Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. , 2007, Journal of clinical psychopharmacology.

[13]  L. Price,et al.  Computer Program Exchange , 2001 .

[14]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[15]  Robert M. Post,et al.  Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP , 1997, Psychiatry Research.

[16]  J. Lindenmayer,et al.  Paliperidone Extended-Release in Schizoaffective Disorder: A Randomized, Controlled Study Comparing a Flexible Dose With Placebo in Patients Treated With and Without Antidepressants and/or Mood Stabilizers , 2010, Journal of clinical psychopharmacology.

[17]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .